TriSalus Life Sciences appoints David Patience as CFO; James Young resigns

TriSalus Life Sciences, Inc.

CFO James Young resigned for personal reasons effective May 30, 2025; receives six months salary and continued equity vesting through May 2026.
David Patience appointed CFO effective July 1, 2025; base salary $450,000, sign-on bonus $159,000, eligible for 50% annual bonus and 1% stock option grant.
Dan Giordano, VP of Finance, serves as acting CFO during transition; Young remains available for orderly handover.
Patience previously CFO at Accelerate Diagnostics; also held roles at Morgan Stanley, Continental Advisors, and Nuveen Investments.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Young

Chief Financial Officer

TLSI · TriSalus Life Sciences, Inc.

Effective: 2025-05-30
Successor: David Patience
Filed: May 30, 2025, 7:59 PM ET

Mr. Young resigned from the Company for personal reasons, effective May 30, 2025.

Appointed

David Patience

Chief Financial Officer

TLSI · TriSalus Life Sciences, Inc.

Effective: 2025-07-01
Filed: May 30, 2025, 7:59 PM ET

On May 27, 2025, the Company entered into an offer letter with David Patience for the position of Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Young resigned as Chief Financial Officer at TriSalus Life Sciences, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Mr. Young resigned from the Company for personal reasons, effective May 30, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Patience was appointed as Chief Financial Officer at TriSalus Life Sciences, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 27, 2025, the Company entered into an offer letter with David Patience for the position of Chief Financial Officer.

View on SEC.gov

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001826667-25-000071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.